At the outset of life sciences transactions, there is usually a strong sense of alignment. Founders and investors tend to agree on the importance of discipline, focus, capital efficiency, and long-term value. That was evident...more
1/21/2026
/ Acquisitions ,
Biotechnology ,
Board of Directors ,
Clinical Trials ,
Contract Terms ,
Corporate Governance ,
Due Diligence ,
Early Stage Companies ,
Equity Financing ,
Exit Planning ,
Healthcare ,
Investment ,
Investment Funds ,
Investors ,
Life Sciences ,
Regulatory Requirements ,
Risk Management ,
Valuation ,
Venture Capital